ten23 health, the human-centric and sustainable CDMO partner of choice for the pharmaceutical and biotechnology industries, today announced that its recently established and Swissmedic approved Quality Control (QC) laboratories in both Basel and Visp, Switzerland, have been formally approved by the U.S. Food and Drug Administration (FDA). The approval was granted in connection with registering ten

Aurealis Therapeutics Announces Positive Blinded Evaluator Efficacy Results of "DIAMEND" Phase-2 Randomized Controlled Trial (NCT06111183 / EU CT 2022-502048-10-00) with AUP-16, a multi-targeting cell & gene therapy for DFUs and other chronic wounds. Results of the study show that AUP-16 Tripling the Complete Wound Closure Rate in Patients with Chronic Diabetic Foot Ulcers with prior wound dur

Macrogen Europe has expanded the capabilities of its Amsterdam laboratory by introducing DNA and RNA extraction from blood samples, available starting January 2, 2026. This new implementation provides a faster and more accessible option for researchers and biotech partners, including the Swiss biotech community.

MUVON Therapeutics AG, a clinical-stage biotechnology company, reports positive topline results from the Phase 2 clinical trial SUISSE-MPC2 (NCT05534269) evaluating its novel proprietary muscle precursor cell (MPC)-based tissue-engineered therapy platform in female stress urinary incontinence (SUI). The study met both its primary and secondary endpoints (p<0.0001), demonstrating significant, cl